Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study
Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2- subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line t...
Salvato in:
Autori principali: | , , , , , , , , , , |
---|---|
Natura: | Libro |
Pubblicazione: |
BioExcel Publishing Ltd,
2024-02-01T00:00:00Z.
|
Soggetti: | |
Accesso online: | Connect to this object online. |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
Collocazione: |
A1234.567 |
---|---|
Copia 1 | Disponibile |